Person:
ÖZGEN, ZÜLEYHA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÖZGEN

First Name

ZÜLEYHA

Name

Filters

20193
Reset filters

Settings

Start date: 2019 × End date: 2019 ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Demographic, clinical and treatment characteristics of patients with Kaposi's sarcoma: A single-center study
    (MARMARA UNIV, FAC MEDICINE, 2019-05-29) SALMAN, ANDAÇ; Salman, Andac; Ozgen, Zuleyha
    Objective: The clinical, demographic and treatment characheristics of patients with Kaposi's sarcoma (KS) are not well-detined. There is lack of consensus on treatment modalities. Thus, we aimed to define demographic, clinical characteristics and treatment outcomes in our cohort of patients with KS. Patients and Methods: A retrospective cohort study was done and all patients who were followed up in our specialized cutaneous tumors outpatient clinic with a diagnosis of KS between 2006 and 2018 were included in the study. Results: A total of 25 patients were included in the study. The mean age of the patients was 66 and 80% were male. The most common form of KS was classic type (80%). During a mean follow-up of 43 months, the most frequently administered treatments were cryotherapy, interferons, radiotherapy, topical imiquimod and topical timolol. Overall a complete response was observed in 9 (36%) patients. Conclusion: The clinical and demographic characteristics of our cohort match those observed in existing literature. We think that the use of local treatments such as cryotherapy, topical imiquimod should be used more frequently in patients with limited disease. Considering the efficacy of timolol in other vascular tumors, future prospective studies investigating the effects of timolol in KS are highly warranted.
  • Thumbnail Image
    PublicationOpen Access
    Effect of Dental Follicle Mesenchymal Stem Cells on Th1 and Th2 Derived Naive T Cells in Atopic Dermatitis Patients
    (MARMARA UNIV, INST HEALTH SCIENCES, 2019-08-31) GÖKER, MEHMET KAMİL; Zibandeh, Noushin; Genc, Deniz; Ozgen, Zuleyha; Duran, Yazgul; Kasap, Nurhan; Goker, Kamil; Baris, Safa; Ergun, Tulin; Akkoc, Tunc
    Objective: The purpose of our study is to investigate the immunomodulatory effects of Dental Follicle Mesenchymal Stem Cells (DF-MSCs) on lymphocytes isolated from peripheral blood of Atopic Dermatitis (AD) patients, a Th2 disease and psoriasis, a Th1 / Th17 disease and compare them with healthy individuals in vitro. Methods: Patients with the AD (n = 9) and psoriasis (n = 6) who are followed up in Marmara University Pediatric Allergy and Immunology and Dermatology outpatient clinics and healthy subjects (n = 6) were included. Peripheral Blood Mononuclear Cells (PBMCs) were isolated from 20 ml of venous blood of all participants. Cells were cultured for 72 hours in the absence and presence of DF-MSCs with anti-CD3/anti-CD28 stimulation or without stimulation. At the end of this period, CD4+ and CD8+ T lymphocyte proliferation and cytokine levels from the culture supernatants were analyzed by flow cytometry. Results: In the presence of DF-MSCs, proliferation ratio was suppressed in both CD4+ and CD8+ cells in AD and psoriasis patients (p<0,05). IFN-gamma levels significantly increased in AD patients in the presence of DF-MSCs (p<0,05) whereas decreased significantly in psoriasis patients in the presence of DF-MSCs (p<0,05). IL-4 levels significantly decreased in AD patients in the presence of DF-MSCs (p<0,05) but remained unchanged in psoriasis patients (p>0,05). IL-10 increased significantly in both groups in the presence of DF-MSCs (p<0,05). Conclusion: Our results support immunoregulatory effects of DF-MSCs on both AD and psoriasis which are Th2 and Th1 / Th17 dominant diseases respectively. Our evidence-based results demonstrated that DF-MSCs could have a beneficial therapeutic implication for inflammatory skin diseases.
  • No Thumbnail Available
    PublicationMetadata only
    Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature
    (WILEY, 2019) ÖZGEN, ZÜLEYHA; Bilgic-Temel, Asli; Ozgen, Zueleyha; Harman, Mehmet; Kapicioglu, Yelda; Uzun, Soner
    Background/Objectives There is inadequate knowledge regarding rituximab (RTX) administration in autoimmune bullous diseases (AIBDs), disease prevalence, clinical characteristics, and treatment outcomes within pediatric populations due to the rarity of AIBDs affecting the pediatric age group. The aim of this retrospective analysis was to evaluate the effectiveness, safety of RTX, and treatment outcomes in Turkish pediatric patients with pemphigus vulgaris (PV) and to review the literature. Methods Five patients under 18 years of age and diagnosed with PV received RTX treatment and were identified in four dermatology departments of Turkey. Results The mean age of the patients at the time of RTX therapy initiation was 15 years (range: 11-17 years), and the total duration of follow-up after RTX therapy was 42.6 months (range: 19-60 months). All patients showed a clinical response. At the last visit, complete remission off therapy was achieved in three patients. The remaining two patients achieved partial remission off therapy. No adverse events were observed. Conclusions This retrospective case series of five pediatric patients showed that RTX treatment can be effective and safe for the treatment of recalcitrant PV in pediatric patients. With increasing evidence, RTX is a good treatment choice in adults and pediatric patients with pemphigus.